In a Phase 1/2a clinical trial (NCT01421186) evaluating felzartamab in 91 adults with relapsed/refractory (r/r) MM, felzartamab reduced M-protein levels, supporting systemic depletion of CD38+ plasma cells [82,87]. This evidence concerns the gene CD38 and Miyoshi myopathy.